Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 23
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Sunshine Biopharma Inc
SBFM
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.1500
-0.017
-10.18%
Dern. MÀJ: Oct 23, 4:26 PM
Get Report
Aperçu
Actualités
Prévisions de résultats
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Rapport sur les stocks
PRO
Pourquoi cela bouge-t-il ?:
ARB IOT Group shares are trading lower after the company announced a 1-for-...
Fractionnement d'actions:
Sunshine Biopharma Inc devrait se scinder Monday, October 26, 2026 avec un ratio de 1:20
Sunshine Biopharma Financials
Sunshine Biopharma (SBFM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Sunshine Biopharma Q1 EPS $(0.44) Up From $(2.00) YoY, Sales $8.90M Up From $7.54M YoY
Benzinga Newsdesk
Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug
Sunshine Biopharma's K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 million.
Vandana Singh
PRO
Sunshine Biopharma 2024 Revenue $34.9M Up From $24.1M YoY
Benzinga Newsdesk
PRO
Sunshine Biopharma Q3 2024 GAAP EPS $(0.94), Sales $8.435M
Benzinga Newsdesk
PRO
Sunshine Biopharma Q2 EPS $(9.94) Misses $(0.37) Estimate, Sales $9.30M Beat $9.00M Estimate
Sunshine Biopharma (NASDAQ:SBFM) reported quarterly losses of $(9.94) per share which missed the analyst consensus estimate of $(0.37) by 2586.49 percent. This is a 86.03 percent increase over losses of $(71.17) per
Benzinga Newsdesk
PRO
Sunshine Biopharma Q1 EPS $(2.00) Misses $(1.04) Estimate, Sales $7.54M Beat $7.00M Estimate
Sunshine Biopharma (NASDAQ:SBFM) reported quarterly losses of $(2.00) per share which missed the analyst consensus estimate of $(1.04) by 92.31 percent. This is a 75 percent increase over losses of $(8.00) per share from
Benzinga Newsdesk
